![Sustained Release Tablets: Matrix Based Sustained Release Formulations of Diclofenac sodium: Amazon.co.uk: Murtaza, Ghulam, S. H. Akash, M., N. H. Shah, S.: 9783843385244: Books Sustained Release Tablets: Matrix Based Sustained Release Formulations of Diclofenac sodium: Amazon.co.uk: Murtaza, Ghulam, S. H. Akash, M., N. H. Shah, S.: 9783843385244: Books](https://m.media-amazon.com/images/I/61TdwyrKoaL.jpg)
Sustained Release Tablets: Matrix Based Sustained Release Formulations of Diclofenac sodium: Amazon.co.uk: Murtaza, Ghulam, S. H. Akash, M., N. H. Shah, S.: 9783843385244: Books
![Advances in mechanistic understanding of release rate control mechanisms of extended-release hydrophilic matrix tablets | Therapeutic Delivery Advances in mechanistic understanding of release rate control mechanisms of extended-release hydrophilic matrix tablets | Therapeutic Delivery](https://www.future-science.com/cms/10.4155/tde-2016-0026/asset/images/medium/figure1.gif)
Advances in mechanistic understanding of release rate control mechanisms of extended-release hydrophilic matrix tablets | Therapeutic Delivery
![Various Modified Tablets | Sustained release tablet | Multilayered tablets | Pharmaceutics DPharm1st - YouTube Various Modified Tablets | Sustained release tablet | Multilayered tablets | Pharmaceutics DPharm1st - YouTube](https://i.ytimg.com/vi/vFgPCsNcWuI/sddefault.jpg)
Various Modified Tablets | Sustained release tablet | Multilayered tablets | Pharmaceutics DPharm1st - YouTube
![Octasa 400 mg Modified Release Tablets (Active substance: mesalazine) used to treat mild to moderate attacks of ulcerative colitis Stock Photo - Alamy Octasa 400 mg Modified Release Tablets (Active substance: mesalazine) used to treat mild to moderate attacks of ulcerative colitis Stock Photo - Alamy](https://c8.alamy.com/comp/WPHK7W/octasa-400-mg-modified-release-tablets-active-substance-mesalazine-used-to-treat-mild-to-moderate-attacks-of-ulcerative-colitis-WPHK7W.jpg)
Octasa 400 mg Modified Release Tablets (Active substance: mesalazine) used to treat mild to moderate attacks of ulcerative colitis Stock Photo - Alamy
![Design and evaluation of an extended-release matrix tablet formulation; the combination of hypromellose acetate succinate and hydroxypropylcellulose - ScienceDirect Design and evaluation of an extended-release matrix tablet formulation; the combination of hypromellose acetate succinate and hydroxypropylcellulose - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1818087616302094-ajps418-fig-0007.jpg)